ASX:NOX
Market Cap:
Price Delay ~20min
Interactive 2020
Annual Report

Media

23-Jul-2020

US online forum BioSpace reports Noxopharm's announcement, " Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting 'Cold' Tumors to 'Hot'.

Click here to read more.

2-Jul-2020

US publication Clinical Research News: the Industry Updates section mentions Noxopharm's planned COVID-19 trial using Veyonda®.

Click here to read more.

30-Jun-2020

Genetic Engineering and Biotechnology News (GEN): reports on Noxopharm's Veyonda® as a potential COVID-19  treatment candidate, noting it as a cGAS-STING signaling pathway inhibitor designed to treat the cytokine storm and septic shock associated with COVID-19.

Click here to read more.

29-Jun-2020

CenterWatch Weekly notes in its COVID-19 Drug Research Roundup - Therapeutics : Noxopharm has begun planning a phase 1 trial of its investigational oncology drug Veyonda(NOX66) in Europe.

Click here to read more.

26-Jun-2020

In more industry news, Pharmaceutical Business Review (UK) highlighted that Noxopharm reports its COVID-19 trial programme planned to commence a Phase 1 trial in Europe.

Click here to read more.

21-Apr-2020

US biotech publication BioWorld highlights Noxopharm’s idronoxil’s ability to block the STING pathway in a potential treatment in the fight against COVID-19.

Click here to read more.

17-Sep-2019

Noxopharm announcement that scientific data from DARRT-1 and LuPIN prostate cancer treatment studies included in two major oncology conferences this year, as covered by Biotech Dispatch

12-Sep-2019

Australian drug development company Noxopharm™ to present interim results on new prostate cancer treatment at specialist oncology conferences in Australia and overseas

30-Aug-2019

US digital medical magazine Healthcare Tech Outlook profiling the enhancing effect of Veyonda on radiotherapy seen in pre-clinical trials and in clinical trials with men with prostate cancer.